Pharmaceutical transfer pricing can use profit splits based on manufacturing, intellectual property and marketing contributions rather than original v...
Inadvertent transfer pricing reporting omissions do not justify penalty where transactions were fully disclosed, benchmarked and accepted at arm's len...
Derivative trading loss disallowance requires transaction-specific evidence of manipulation once primary records discharge the taxpayer's initial burd...
A technical or inadvertent omission to separately report an...
Inadvertent transfer pricing reporting omissions do not justify penalty where transactions were fully disclosed, benchmarked and accepted at arm's length.
Contents
Summary
Note
Bookmark
Share
✓ Copied successfully !
(New)
Download
Print
Print Options
For full text, please login
Login to TaxTMI
Verification Pending
The Email Id has not been verified. Click on the link we have sent on
A technical or inadvertent omission to separately report an amount retained by an associated enterprise for marketing services in Form 3CEB does not justify a penalty under section 271AA(1) where the full transaction was documented, disclosed and benchmarked in the transfer pricing study. The arrangement was examined and accepted at arm's length without adjustment, with no finding of inadequate documentation or concealment and no revenue loss.
A technical or inadvertent omission to separately report an amount retained by an associated enterprise for marketing services in Form 3CEB does not justify a penalty under section 271AA(1) where the full transaction was documented, disclosed and benchmarked in the transfer pricing study. The arrangement was examined and accepted at arm's length without adjustment, with no finding of inadequate documentation or concealment and no revenue loss.
Note: It is a system-generated summary and is for quick reference only.